Michael Makris/LinkedIn
Mar 2, 2026, 13:42
Michael Makris: How Early Can Hemlibra Be Started?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Eman Hassan et al, published in RPTH Journal:
”How early can you start Hemlibra (emicizumab)?
A paper in the RPTH Journal describes its effective use when started at 26 hours of age, in a baby with hemophilia born 10 weeks premature (at 30 weeks of gestation).”
Title: Emicizumab Prophylaxis in a Preterm Infant with Severe Haemophilia A: A Case Report on the Feasibility of Early Use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal․
Other articles featuring Michael Makris on Hemostasis Today.
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting
-
Jun 1, 2026, 13:23Skye Collado: Miller-Keystone Blood Center Expands Community Impact Through the Addition of New Bloodmobiles
-
Jun 1, 2026, 12:37Rutuja Mahadik: Anemia is More Than Just Feeling Tired
-
Jun 1, 2026, 12:36Ankur Jindal: Large-Vessel Inflammation and Immune Dysregulation in Wiskott–Aldrich Syndrome
-
Jun 1, 2026, 12:35Shadi Almassri: Conditions That Can Cause False High or False Low HbA1c Results
-
Jun 1, 2026, 12:22Ed Davidson: Clot Removing Technology That Can Change the Game